NASDAQ:FATEFate Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fate Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $32.84 +0.22 (+0.67 %) (As of 08/5/2020 04:00 PM ET) Add Compare Share Today's Range$32.47Now: $32.84▼$33.2050-Day Range$30.78MA: $33.73▼$37.7152-Week Range$12.59Now: $32.84▼$38.52Volume595,691 shsAverage Volume1.06 million shsMarket Capitalization$2.55 billionP/E RatioN/ADividend YieldN/ABeta1.69 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingFate Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.27, Fate Therapeutics has a potential upside of 13.5% from its current price of $32.84.Amount of Analyst CoverageFate Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesFate Therapeutics has received 416 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFate Therapeutics has received 283 “underperform” votes. (Add your “underperform” vote.)Community SentimentFate Therapeutics has received 59.51% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote “Outperform” if you believe FATE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFate Therapeutics does not currently pay a dividend.Dividend GrowthFate Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fate Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $39,999,992.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 21.41% of the stock of Fate Therapeutics is held by insiders.Percentage Held by Institutions97.33% of the stock of Fate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Fate Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fate Therapeutics is -20.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fate Therapeutics is -20.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFate Therapeutics has a P/B Ratio of 10.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.89 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FATE Previous Symbol CUSIPN/A CIK1434316 Webwww.fatetherapeutics.com Phone858-875-1800Debt Debt-to-Equity Ratio0.34 Current Ratio8.36 Quick Ratio8.36Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10.68 million Price / Sales238.90 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book10.14Profitability EPS (Most Recent Fiscal Year)($1.44) Net Income$-98,150,000.00 Net Margins-1,059.44% Return on Equity-52.08% Return on Assets-38.45%Miscellaneous Employees104 Outstanding Shares77,692,000Market Cap$2.55 billion Next Earnings Date8/5/2020 (Confirmed) OptionableOptionable $32.84 +0.22 (+0.67 %) (As of 08/5/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive FATE News and Ratings via Email Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions How has Fate Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Fate Therapeutics' stock was trading at $23.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FATE shares have increased by 38.0% and is now trading at $32.84. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Fate Therapeutics? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 hold rating and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fate Therapeutics. When is Fate Therapeutics' next earnings date? Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Fate Therapeutics. How were Fate Therapeutics' earnings last quarter? Fate Therapeutics Inc (NASDAQ:FATE) released its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.05. The biopharmaceutical company earned $2.52 million during the quarter, compared to analyst estimates of $1.69 million. Fate Therapeutics had a negative net margin of 1,059.44% and a negative return on equity of 52.08%. The company's quarterly revenue was down 4.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.30) EPS. View Fate Therapeutics' earnings history. What price target have analysts set for FATE? 14 brokers have issued 1-year target prices for Fate Therapeutics' shares. Their forecasts range from $25.00 to $59.00. On average, they expect Fate Therapeutics' stock price to reach $37.27 in the next year. This suggests a possible upside of 13.5% from the stock's current price. View analysts' price targets for Fate Therapeutics. Has Fate Therapeutics been receiving favorable news coverage? Headlines about FATE stock have trended neutral this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fate Therapeutics earned a news impact score of 0.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Fate Therapeutics. Who are some of Fate Therapeutics' key competitors? Some companies that are related to Fate Therapeutics include Novavax (NVAX), Repligen (RGEN), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), bluebird bio (BLUE), Sorrento Therapeutics (SRNE) and Twist Bioscience (TWST). View all competitors. What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Juno Therapeutics (JUNO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Exelixis (EXEL), Gilead Sciences (GILD), TG Therapeutics (TGTX) and Clovis Oncology (CLVS). Who are Fate Therapeutics' key executives? Fate Therapeutics' management team includes the following people: J. Scott Wolchko, President, Chief Executive Officer & DirectorDaniel D. Shoemaker, Chief Scientific OfficerYu Waye Chu, Vice President-Clinical DevelopmentJim Beitel, Senior Vice President-Corporate DevelopmentBahram Valamehr, Chief Development Officer What is Fate Therapeutics' stock symbol? Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE." Who are Fate Therapeutics' major shareholders? Fate Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.69%), Columbus Circle Investors (0.35%), Swiss National Bank (0.17%), Alps Advisors Inc. (0.14%), First Trust Advisors LP (0.10%) and Russell Investments Group Ltd. (0.09%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View institutional ownership trends for Fate Therapeutics. Which institutional investors are selling Fate Therapeutics stock? FATE stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Vident Investment Advisory LLC, Vident Investment Advisory LLC, Alps Advisors Inc., Russell Investments Group Ltd., SG Americas Securities LLC, First Trust Advisors LP, and Virtus ETF Advisers LLC. Company insiders that have sold Fate Therapeutics company stock in the last year include Bahram Valamehr, Cindy Tahl, and J Scott Wolchko. View insider buying and selling activity for Fate Therapeutics. Which institutional investors are buying Fate Therapeutics stock? FATE stock was acquired by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Assenagon Asset Management S.A., Mackay Shields LLC, Swiss National Bank, Principal Financial Group Inc., ProShare Advisors LLC, Vigilare Wealth Management, and Strs Ohio. View insider buying and selling activity for Fate Therapeutics. How do I buy shares of Fate Therapeutics? Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Fate Therapeutics' stock price today? One share of FATE stock can currently be purchased for approximately $32.84. How big of a company is Fate Therapeutics? Fate Therapeutics has a market capitalization of $2.55 billion and generates $10.68 million in revenue each year. The biopharmaceutical company earns $-98,150,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe. What is Fate Therapeutics' official website? The official website for Fate Therapeutics is www.fatetherapeutics.com. How can I contact Fate Therapeutics? Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected] This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
